{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:06:25Z","timestamp":1777421185632,"version":"3.51.4"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,10]]},"DOI":"10.1097\/meg.0b013e3283154f3a","type":"journal-article","created":{"date-parts":[[2009,9,11]],"date-time":"2009-09-11T07:13:45Z","timestamp":1252653225000},"page":"1177-1183","source":"Crossref","is-referenced-by-count":6,"title":["Current trends in chronic hepatitis B management: results of a questionnaire"],"prefix":"10.1097","volume":"21","author":[{"given":"I\u00f1igo","family":"Les","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rita","family":"Garc\u00eda-Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"C\u00f3rdoba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuel","family":"Quintana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rafael","family":"Esteban","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda","family":"Buti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-12-20210207","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1002\/hep.21513","article-title":"Chronic hepatitis B","volume":"45","author":"Lok","year":"2007","journal-title":"Hepatology"},{"key":"R2-12-20210207","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1002\/hep.21627","article-title":"Management of hepatitis B: summary of a clinical research","volume":"45","author":"Hoofnagle","year":"2007","journal-title":"Hepatology"},{"key":"R3-12-20210207","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1056\/NEJM199910213411702","article-title":"Lamivudine as initial treatment for chronic hepatitis B in the United States","volume":"341","author":"Dienstag","year":"1999","journal-title":"N Engl J Med"},{"key":"R4-12-20210207","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1177\/135965350701200308","article-title":"Two-year lamivudine treatment for hepatitis B e antigen-negative chronic hepatitis B: a double-blind, placebo-controlled trial","volume":"12","author":"Chan","year":"2007","journal-title":"Antivir Ther"},{"key":"R5-12-20210207","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1056\/NEJMoa020681","article-title":"Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B","volume":"348","author":"Marcellin","year":"2003","journal-title":"N Engl J Med"},{"key":"R6-12-20210207","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1056\/NEJMoa021812","article-title":"Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B","volume":"348","author":"Hadziyannis","year":"2003","journal-title":"N Engl J Med"},{"key":"R7-12-20210207","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJMoa051285","article-title":"A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B","volume":"354","author":"Chang","year":"2006","journal-title":"N Engl J Med"},{"key":"R8-12-20210207","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1056\/NEJMoa051287","article-title":"Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B","volume":"354","author":"Lai","year":"2006","journal-title":"N Engl J Med"},{"key":"R9-12-20210207","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.1056\/NEJMoa066422","article-title":"Telvibudine versus lamivudine in patients with chronic hepatitis B","volume":"357","author":"Lai","year":"2007","journal-title":"N Engl J Med"},{"key":"R10-12-20210207","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/j.cld.2007.08.003","article-title":"Oral antivirals for chronic hepatitis B","volume":"11","author":"Min","year":"2007","journal-title":"Clin Liver Dis"},{"key":"R11-12-20210207","doi-asserted-by":"crossref","first-page":"2682","DOI":"10.1056\/NEJMoa043470","article-title":"Peginterferon alfa-2a, lamivudine, and the combination for HbeAg-positive chronic hepatitis","volume":"352","author":"Lau","year":"2005","journal-title":"N Engl J Med"},{"key":"R12-12-20210207","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1056\/NEJMoa040431","article-title":"Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HbeAg-negative chronic hepatitis B","volume":"351","author":"Marcellin","year":"2004","journal-title":"N Engl J Med"},{"key":"R13-12-20210207","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1002\/hep.21253","article-title":"Adefovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy","volume":"44","author":"Van B\u00f6mmel","year":"2006","journal-title":"Hepatology"},{"issue":"2","key":"R14-12-20210207","doi-asserted-by":"crossref","first-page":"216S","DOI":"10.1157\/13097663","article-title":"Consensus document of the Spanish Association for the Study of the Liver on the treatment of hepatitis B and C virus infections","volume":"29","author":"Bruguera","year":"2006","journal-title":"Gastroenterol Hepatol"},{"key":"R15-12-20210207","first-page":"1","article-title":"Advisory Committee on Immunization Practices (ACIP). A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) part 1: immunization of infants, children and adolescents","volume":"54","author":"Mast","year":"2005","journal-title":"MMWR Recomm Rep"},{"key":"R16-12-20210207","first-page":"1","article-title":"Advisory Committee on Immunization Practices (ACIP) Centers for Disease Control and Prevention (CDC). A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: immunization of adults","volume":"55","author":"Mast","year":"2006","journal-title":"MMWR Recomm Rep"},{"key":"R17-12-20210207","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1002\/jmv.20744","article-title":"Molecular and epidemiological characteristics of blood-borne virus infections among recent immigrants in Spain","volume":"78","author":"Toro","year":"2006","journal-title":"J Med Virol"},{"key":"R18-12-20210207","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1002\/hep.510300328","article-title":"Current practice patterns of primary care physicians in the management of patients with hepatitis C","volume":"30","author":"Shehab","year":"1999","journal-title":"Hepatology"},{"key":"R19-12-20210207","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1471-230X-4-3","article-title":"Primary care physician's approach to diagnosis and treatment of hepatitis B and hepatitis C patients","volume":"4","author":"Peksen","year":"2004","journal-title":"BMC Gastroenterol"},{"key":"R20-12-20210207","first-page":"333","article-title":"What barriers do primary care physicians face in the management of patients with chronic hepatitis B infection in primary care?","volume":"46","author":"Tan","year":"2005","journal-title":"Singapore Med J"},{"issue":"1","key":"R21-12-20210207","first-page":"1S","article-title":"Which patients with chronic hepatitis B are treated and how: a cross-sectional study in France on 1790 patients","volume":"46","author":"Marcellin","year":"2007","journal-title":"J Hepatol"},{"key":"R23-12-20210207","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1002\/1096-9071(200011)62:3<299::AID-JMV1>3.0.CO;2-0","article-title":"Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors","volume":"62","author":"Yeo","year":"2000","journal-title":"J Med Virol"},{"key":"R24-12-20210207","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1002\/hep.21051","article-title":"Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy","volume":"43","author":"Yeo","year":"2006","journal-title":"Hepatology"},{"key":"R25-12-20210207","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1053\/j.gastro.2003.09.026","article-title":"Preemptive lamivudine in hepatitis B patients undergoing chemotherapy","volume":"125","author":"Del Poggio","year":"2003","journal-title":"Gastroenterology"},{"key":"R26-12-20210207","doi-asserted-by":"crossref","first-page":"312","DOI":"10.7326\/0003-4819-119-4-199308150-00011","article-title":"Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis","volume":"119","author":"Wonk","year":"1993","journal-title":"Ann Intern Med"},{"key":"R27-12-20210207","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1046\/j.1365-2893.2003.00450.x","article-title":"Peginterferon alpha-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B","volume":"10","author":"Cooksley","year":"2003","journal-title":"J Viral Hepat"},{"key":"R28-12-20210207","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/S0168-8278(00)00094-5","article-title":"The long-term outcome of interferon-alpha treated and untreated patients with HBeAg-negative chronic hepatitis B","volume":"34","author":"Papatheodoridis","year":"2001","journal-title":"J Hepatol"},{"key":"R29-12-20210207","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1053\/j.gastro.2003.10.051","article-title":"Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B","volume":"126","author":"Peters","year":"2004","journal-title":"Gastroenterology"},{"key":"R30-12-20210207","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1177\/135965350601100604","article-title":"Virological response and incidence of adefovir resistance in lamivudine-resistant patients treated with adefovir dipivoxil","volume":"11","author":"Chen","year":"2006","journal-title":"Antivir Ther"}],"container-title":["European Journal of Gastroenterology &amp; Hepatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00042737-200910000-00012","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,16]],"date-time":"2024-03-16T12:29:20Z","timestamp":1710592160000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00042737-200910000-00012"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,10]]},"references-count":29,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2009]]}},"URL":"https:\/\/doi.org\/10.1097\/meg.0b013e3283154f3a","relation":{},"ISSN":["0954-691X"],"issn-type":[{"value":"0954-691X","type":"print"}],"subject":[],"published":{"date-parts":[[2009,10]]}}}